Denmark discusses vaccine swap with other countries
Denmark is currently discussing swapping the Astrazeneca vaccine for other vaccines with multiple countries.
MedWatch
A part of Watch Medier
Denmark is currently discussing swapping the Astrazeneca vaccine for other vaccines with multiple countries.
Denmark’s decision to stop using the Astrazeneca vaccine is one that health organizations can understand, However, they say it can prolong the corona crisis – and sends a poor signal to others.
The EU is negotiating with Pfizer/Biontech and Moderna for new vaccine contracts, states French economy minister, but it's unlikely the union it will reach out to Astrazeneca or Johnson & Johnson.
Recent concerns on whether Denmark is properly protected in terms of access to vaccines have been implemented in the new national Danish life science strategy which was presented early Friday. The strategy mentions partnerships with the life science industry to strengthen vaccine access.
According to the WHO, Denmark is looking into the possibility of sharing its doses of the Astrazeneca vaccine with developing countries after the vaccine has been discontinued in the Danish vaccine program.
The Danish Health Authority deems that the continued use of the 200,000 Astrazeneca vaccines which Denmark has in stock will prevent one hospitalization but lead to five blood clots.
At a press conference, the Danish Health Authority states that the vaccine from Astrazeneca will be removed from Denmark's vaccination program.
It's too early to say whether the technology used in two vaccines will trigger a particular pathological picture, says Danish head of unit.
French residents under the age of 55 who have received the first jab of Astrazeneca's vaccine will get their second injection with a different vaccine.
The EMA's Astrazeneca-related announcement will not influence the Danish pause of Astrazeneca vaccines.
The EMA has announced that it sees a possible connection between Astrazeneca's Covid-19 vaccine and some highly rare cases of blood clots following vaccinations, but it maintains its recommendations to keep using the vaccine.
Insulin producers Novo Nordisk, Sanofi and Eli Lilly have come under attack from Democratic Party representatives in the US who have encouraged the US Federal Trade Commission to investigate them for potential collusion in the US insulin market.
In the first quarter, Astrazeneca was meant to provide vaccines in the triple-digit millions, and the company has to deliver, says Ursula von der Leyen.
On Thursday, Lundbeck lost an appeal case at the European Court of Justice for a EUR 93.7m fine which the firm paid in 2013.
Following 'thorough investigations' the Danish Competition and Consumer Authority has approved that Orifarm can take over a range of drugs and factories from Japanese Takeda. However, in return, the firm has to divest several products and rights.
The new export rules comes as the health outlook has dramatically worsened in Europe, with many of the biggest countries including Germany and France announcing new lockdowns.
The FDA has refused to start filing Novo Nordisk's application for an expanded marketing authorization for Ozempic in a higher dose.
In 2022, Bavarian Nordic will start shipping a new smallpox vaccine order to the Canadian government. This order will not have any new effect on the company's guidance this year.
Cross Functional CMC/Safety Toxicologist, Ascendis Pharma 
Senior QMS Professional in Project- and Change Management - ALK 
Sponsor Oversight Lead - Genmab Pharmacovigilance Auditor - ALK 
Senior Manager, Regulatory Affairs CMC, New Markets & Life Cycle Management - Y-mAbs Therapeutics 
Manager, SOX Compliance - Zealand Pharma Development Chemist for Drug Product Development - ALK 
Senior Scientist, Neuroimmunology and Neuroinflammation, In-vivo, Lundbeck Associate Director, GMP QA, Commercial Operations – Y-mAbs Therapeutics eTMF Manager - Genmab Senior Scientist (Toxicology) / Nonclinical Safety Specialist Senior Manager, QA GMP - Genmab Senior QA Manager, QA Commercial Operations, Ascendis Pharma 
Regulatory Affairs Specialist - Orifarm 
System Engineer for novel stem cell devices - Novo Nordisk Pharmacovigilance Director - Zealand Pharma Business Process Manager - Orifarm Statistical Programmer, Specialist - Lundbeck 
Director of Global Marketing - Ascelia Pharma R&D Process Manager - Genmab Project Manager, Unilabs 
Electronics / HW Engineer for the development of medical devices Mechanical Design Engineer, with solid experience in 3D CAD Senior Laborant with responsibility for operation and task coordination Regulatory Affairs Associate - Orifarm